Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.43 |
| ▸ | GCLC | P48506 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28619584 | 0.85 | CA2 (0.61) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL5526716 | 0.84 | CHRM1 (0.70) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL19528699 | 0.84 | CHRM1 (0.42) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL28000329 | 0.83 | — | — | |
| SCHEMBL10897254 | 0.80 | CA2 (0.81) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL14360108 | 0.80 | CA2 (0.81) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL6441158 | 0.80 | FOLH1 (0.56) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| Chloromethane SCHEMBL28143162 | 0.80 | CA2 (0.64) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL125406 | 0.80 | CA2 (0.71) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL6114 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4641061-A1 | OIL-WELL METAL PIPE | NIPPON STEEL CORPORATION (JP) | 2025-10-29 | — | — | EP | claimed |
| WO-2024135464-A1 | OIL-WELL METAL PIPE | 日本製鉄株式会社 | 2024-06-27 | — | — | WO | claimed |
| EP-4641061-A1 | OIL-WELL METAL PIPE | NIPPON STEEL CORPORATION (JP) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024135464-A1 | OIL-WELL METAL PIPE | 日本製鉄株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-9029405-B2 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(SIP)receptors | MERCK SERONO S.A. (CH) | 2015-05-12 | — | — | US | disclosed |
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | MERCK SERONO S.A. (CH) | 2013-05-09 | — | — | US | disclosed |
| US-20100173241-A1 | POSITIVELY-CHARGEABLE TONER FOR DEVELOPING ELECTROSTATIC IMAGE | ZEON CORPORATION (JP) | 2010-07-08 | — | — | US | disclosed |
| EP-0948523-B1 | PEPTIDOMIMETIC INHIBITORS OF THE HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-6291640-B1 | OLIGOPEPTIDES; SOLID PHASE SYNTHESIS | BOEHRINGER INGELHEIM LTD. (CA) | 2001-09-18 | — | — | US | disclosed |
| US-6194143-B1 | MEASUREMENT ACTIVITY BY MONITORING SUBSTRATE CLEAVAGE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-02-27 | — | — | US | disclosed |
| EP-0948640-A2 | IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-10-13 | — | — | EP | disclosed |
| EP-0948523-A1 | PEPTIDOMIMETIC INHIBITORS OF THE HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029562-A2 | IMPROVED SUBSTRATES FOR HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-07-09 | — | — | WO | disclosed |
| WO-1998029435-A1 | PEPTIDOMIMETIC INHIBITORS OF THE HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-07-09 | — | — | WO | disclosed |
| US-3932285-A | MONOCARBOXYLIC ACID | TENNECO CHEMICALS, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | S1PR1, S1PR5, S1PR2 | CA2 3783/4885MAPK1 1170/4885CHRM1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.